[1]程 林.低剂量替格瑞洛治疗稳定型冠心病患者的疗效及安全性评价[J].医学信息,2020,33(08):161-162.[doi:10.3969/j.issn.1006-1959.2020.08.053]
　CHENG Lin.Efficacy and Safety of Low-dose Ticagrelor in the Treatment of Stable Coronary Heart Disease[J].Medical Information,2020,33(08):161-162.[doi:10.3969/j.issn.1006-1959.2020.08.053]
点击复制

低剂量替格瑞洛治疗稳定型冠心病患者的疗效及安全性评价()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
33卷
期数:
2020年08期
页码:
161-162
栏目:
药物与临床
出版日期:
2020-04-15

文章信息/Info

Title:
Efficacy and Safety of Low-dose Ticagrelor in the Treatment of Stable Coronary Heart Disease
文章编号:
1006-1959（2020）08-0161-02
作者:
程 林
（佳木斯市中心医院心内一科，黑龙江 佳木斯 154702）
Author(s):
CHENG Lin
(Department of Cardiology,Subject One,Jiamusi Central Hospital,Jiamusi 154702,Heilongjiang,China)
关键词:
低剂量; 替格瑞洛; 稳定型; 冠心病; 安全性
Keywords:
Low dose; Ticagrelor; Stable; Coronary heart disease; Safety
分类号:
R541.4
DOI:
10.3969/j.issn.1006-1959.2020.08.053
文献标志码:
A
摘要:
目的 分析稳定型冠心病临床采用低剂量替格瑞洛治疗的疗效与安全性。方法 选取2018年3月~2019年3月在我院治疗的75稳定型冠心病患者为研究对象，采用随机数字表法分为A组、B组、C组三组，各25例，A组给予硫酸氢氯吡格雷片75 mg/次，1次/d治疗，B组给予替格瑞洛片90 mg/次，2次/d，治疗，C组采用替格瑞洛片45 mg/次，2次/d治疗，比较三组临床治疗总有效率、治疗前与治疗7 d后血小板聚集率、不良心脑血管事件（心肌梗死、卒中、出血）发生情况。结果 B组（96.00%）、C组（92.00%）总有效率均高于A组（76.00%）（P＜0.05）；C组与B组比较，差异无统计学意义（P＞0.05）；治疗前A组、B组、C组血小板聚集率比较，差异无统计学意义（P＞0.05），治疗7 d后B组、C组血小板聚集率均低于A组（P＜0.05），C组与B组比较，差异无统计学意义（P＞0.05）；三组治疗和随访期间均未出现严重不良反应，差异无统计学意义（P＞0.05）。结论 临床采用低剂量替格瑞洛治疗稳定型冠心病疗效确切，抗血小板效果良好，且可有效预防不良心脑血管事件发生。
Abstract:
Objective To analyze the efficacy and safety of low-dose ticagrelor in clinical treatment of stable coronary heart disease.Methods The 75 patients with stable coronary heart disease treated in our hospital from March 2018 to March 2019 were selected as the research object, and they were divided into three groups of group A, group B, and group C by random number table method, with 25 cases in each group.Group A was given clopidogrel bisulfate tablets 75 mg/time, once a day, group B was given ticagrelor tablets 90 mg/time, twice a day, and group C was given ticagrelor tablets 45 mg/time, 2 times/d treatment,compare the total clinical treatment efficiency of three groups, the platelet aggregation rate before treatment and 7 d after treatment, and the occurrence of adverse cardiovascular and cerebrovascular events (myocardial infarction, stroke, bleeding).Results The total effective rate of group B (96.00%) and group C (92.00%) was higher than that of group A (76.00%) (P＜0.05); the difference between group C and group B was not statistically significant (P＞0.05); before treatment, there was no statistically significant difference in platelet aggregation rate between group A, group B and group C (P＞0.05).After 7 d of treatment, the platelet aggregation rate in group B and group C was lower than that in group A(P＜0.05). There was no statistically significant difference between group C and group B (P＞0.05); no serious adverse reactions occurred in the three groups during treatment and follow-up,the difference was not statistically significant (P＞0.05).Conclusion Low-dose ticagrelor is effective in the treatment of stable coronary heart disease, with good antiplatelet effect, and can effectively prevent the occurrence of adverse cardiovascular and cerebrovascular events.

参考文献/References:

[1]李志强,王学惠,常红娟.银杏酮酯滴丸联合替格瑞洛治疗冠心病心绞痛的临床研究[J].现代药物与临床,2019,34(2):360-365.[2]王珂.替格瑞洛与氯吡格雷在冠心病PCI术后的应用比较[J].临床医药实践,2019(2):119-122.[3]贾其威.替格瑞洛与波立维治疗冠心病PCI术后患者血液流变学变化比较[J].医学理论与实践,2018,31(24):3670-3672.[4]刘豪.替格瑞洛联合阿司匹林在冠心病介入治疗患者中的应用效果观察[J].首都食品与医药,2018,25(23):38.[5]王志永.阿司匹林联合小剂量氯吡格雷双联抗血小板治疗在术年后长期随诊观察[D].天津医科大学,2014,11(10):178-180.

相似文献/References:

[1]刘 华,康美尼,王兴华,等.替格瑞洛对oxLDL诱导的人脐静脉内皮细胞ICAM-1表达的影响[J].医学信息,2018,31(22):81.[doi:10.3969/j.issn.1006-1959.2018.22.022]
　LIU Hua,KANG Mei-ni,WANG Xing-hua,et al.Effect of Ticagrelor on the Expression of ICAM-1 in Human umbilical Vein Endothelial Cells Induced by oxLDL[J].Medical Information,2018,31(08):81.[doi:10.3969/j.issn.1006-1959.2018.22.022]
[2]张 毅.替格瑞洛对不稳定型心绞痛患者PCI术后缺血事件及炎症因子水平的影响[J].医学信息,2022,35(13):130.[doi:10.3969/j.issn.1006-1959.2022.13.030]
　ZHANG Yi.Effect of Ticagrelor on Ischemic Events and Inflammatory Factors in Patients with Unstable Angina Pectoris After PCI[J].Medical Information,2022,35(08):130.[doi:10.3969/j.issn.1006-1959.2022.13.030]
[3]刘书斌,刘云庚,陈财福,等.低剂量mFOLFOX6联合同步三维适形放疗在T3期直肠癌术前治疗中的可行性[J].医学信息,2019,32(22):109.[doi:10.3969/j.issn.1006-1959.2019.22.035]
　LIU Shu-bin,LIU Yun-geng,CHEN Cai-fu,et al.Feasibility of Low-dose mFOLFOX6 Combined with Synchronous Three-dimensional Conformal Radiotherapy for Preoperative Treatment of Rectal Cancer in Stage T3[J].Medical Information,2019,32(08):109.[doi:10.3969/j.issn.1006-1959.2019.22.035]
[4]王 焕.替格瑞洛在氯吡格雷抵抗AMI患者PCI术后抗血小板治疗中的应用[J].医学信息,2019,32(24):153.[doi:10.3969/j.issn.1006-1959.2019.24.055]
　WANG Huan.Application of Ticagrelor in the Antiplatelet Therapy of Clopidogrel in Patients with AMI after PCI[J].Medical Information,2019,32(08):153.[doi:10.3969/j.issn.1006-1959.2019.24.055]
[5]吴浩瑜.院前急救中应用不同抗血小板药物组合对ST段抬高型急性心肌梗死患者近期心血管事件的影响[J].医学信息,2021,34(22):57.[doi:10.3969/j.issn.1006-1959.2021.22.016]
　WU Hao-yu.Effects of Different Antiplatelet Drug Combinations in Pre-hospital Emergency Treatment on Recent Cardiovascular Events in Patients with ST-segment Elevation Acute Myocardial Infarction[J].Medical Information,2021,34(08):57.[doi:10.3969/j.issn.1006-1959.2021.22.016]
[6]程 林.替格瑞洛对冠心病患者PCI治疗术后冠脉微循环功能的影响[J].医学信息,2020,33(07):156.[doi:10.3969/j.issn.1006-1959.2020.07.051]
　CHENG Lin.Effect of Ticagrelor on Coronary Microcirculation Function in Patients with Coronary Heart Disease After PCI Treatment[J].Medical Information,2020,33(08):156.[doi:10.3969/j.issn.1006-1959.2020.07.051]

更新日期/Last Update: 2020-04-15